about
High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell linesSmall molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathwaySelective inhibition of BET bromodomainsAn activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cellsSYK is a critical regulator of FLT3 in acute myeloid leukemiaStructural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alphaTargeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signalingDirect inhibition of the NOTCH transcription factor complexIdentification of AML1-ETO modulators by chemical genomicsDiscovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR , Kit, and Src kinases: novel type II inhibitor of gatekeeper mutantsA murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.BET bromodomain inhibition as a therapeutic strategy to target c-MycCyclin D1 represses p300 transactivation through a cyclin-dependent kinase-independent mechanismMediator kinase inhibition further activates super-enhancer-associated genes in AMLSignature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcomaMicroenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translationDicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencingA stapled BIM peptide overcomes apoptotic resistance in hematologic cancers.CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.p53 targets simian virus 40 large T antigen for acetylation by CBPExpression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation.The F-box protein beta-TrCp1/Fbw1a interacts with p300 to enhance beta-catenin transcriptional activity.Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer.Proteomic and genetic approaches identify Syk as an AML target.Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemiaDiscovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma.Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.Smac mimetics: implications for enhancement of targeted therapies in leukemiaSelective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.Risk Factors for Subtherapeutic Tacrolimus Levels after Conversion from Continuous Intravenous Infusion to Oral in Children after Allogeneic Hematopoietic Cell Transplantation.Survival Impact of Early Post-Transplant Toxicities in Pediatric and Adolescent Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Malignant and Nonmalignant Diseases: Recognizing Risks and Optimizing OutcomesComputational repositioning and preclinical validation of pentamidine for renal cell cancer.Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinibInactivation of a single copy of Crebbp selectively alters pre-mRNA processing in mouse hematopoietic stem cells.BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemiaMLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.Differentiation of NUT midline carcinoma by epigenomic reprogramming.Polyubiquitination of p53 by a ubiquitin ligase activity of p300.
P50
Q23058134-09CB4C04-7C10-49D6-B7BB-269FC1301A70Q24299670-96CDBAB6-1164-4C69-B0F8-E0ACE1C4B215Q24301009-BDB99790-D7AC-4C25-8689-B84BD5DF60A4Q24302462-A62610CF-9C1C-4AE0-90B2-2F4EF06DBB2BQ24337247-446A4F39-55C1-4BAF-81D8-15A4772D2109Q24534120-06F03BC8-81AB-4384-B10B-D4D6E5DF9F99Q24632740-670E08E3-320B-4909-9A76-5773C6BC8D32Q24634015-D875AC7D-FA49-4D35-88D0-2A9FFBDAD93CQ24643359-334CEC8E-0DD0-4BC8-A884-20E164CFF6ADQ27660281-16C49D23-F721-4A16-99DF-8BE6EC8CA55FQ27851728-6ACE8A93-742D-4D3B-B54B-DA54BEF7D190Q28247024-66C7E594-705C-460F-8317-CF818E2F6CD1Q28256059-EF3047C0-1088-45FD-A7D3-2B2907C476AAQ28267938-DB9F2809-B73E-45E4-BD49-10CF20C70294Q28469179-0E7AEBA0-3123-4112-86D6-F650B9471296Q28478937-D46DBD33-A4B7-46E1-8FE2-468E72D97406Q28594776-8C7214C5-7861-4305-9F32-CF79646E724FQ30466831-F537965E-9AA8-444F-A108-7327F5949D37Q30487339-D51E5762-401A-438F-882D-85284824DC13Q33292247-92F5C3F3-BE1A-4F56-B84F-FBE0DC72C9F9Q33349703-C44B686E-A061-4068-8496-94A0E32684B2Q33419571-CA511259-B2FC-423F-93D5-EE2611175947Q33421665-C6ED9BEF-C42F-4BB4-BD4B-4EBBC747B195Q33577098-E90CDB32-0785-4A02-A7AF-D49AFAF9F904Q33594629-C98E2C53-A5E9-4F75-AE55-8BA7B484005DQ33601156-D64526FB-382A-4635-973B-50B68401A583Q33621610-A79B2208-68F7-4D10-8B02-4F01EB37F6F0Q33683159-58B6F726-D25B-469C-AB1D-187024CA518AQ33716402-598B7E92-3E23-4649-BEA1-CD14342639D3Q33745075-75D9A890-1940-4032-A90B-EC5B592A2711Q33864145-A1F965E6-E5BB-44CC-BB6E-21680311F0F9Q33870334-6B771E84-A047-49D3-BC38-208E674CDF87Q33870341-8448AC77-250C-474C-ADDC-7A32EC603754Q33875574-8D88C625-D1D9-4E7A-BD8D-C6C8BF99ECABQ34013386-8CDA65F9-16C4-4FB4-8CBE-C61869B7128DQ34013832-7980635B-CCE2-4EE3-9BA5-F2869B8A8C82Q34033206-AE9F0BBD-FC93-4853-9940-EFC9F28FB3DFQ34113855-956E05B5-7C05-49AF-A157-74AEA163750CQ34174143-4D262068-EF4B-403C-84BE-4C04B886484FQ34190044-ECADB540-A9F5-4B06-A6D3-AE575E2FBE70
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Andrew L. Kung
@ast
Andrew L. Kung
@en
Andrew L. Kung
@es
Andrew L. Kung
@nl
type
label
Andrew L. Kung
@ast
Andrew L. Kung
@en
Andrew L. Kung
@es
Andrew L. Kung
@nl
prefLabel
Andrew L. Kung
@ast
Andrew L. Kung
@en
Andrew L. Kung
@es
Andrew L. Kung
@nl
P108
P106
P108
P1153
26642922400
P21
P31
P496
0000-0002-9091-488X